{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:55:44Z","timestamp":1789217744166,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000182","name":"Medical Research and Materiel Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1074\/jbc.ra120.014960","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T22:45:20Z","timestamp":1607035520000},"page":"100157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition"],"prefix":"10.1016","volume":"296","author":[{"given":"Roberta L.","family":"Beauchamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Erdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-817X","authenticated-orcid":false,"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6419","authenticated-orcid":false,"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0681-9263","authenticated-orcid":false,"given":"James F.","family":"Gusella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-5268","authenticated-orcid":false,"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.RA120.014960_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1074\/jbc.RA120.014960_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet. Med."},{"key":"10.1074\/jbc.RA120.014960_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.spen.2015.10.008","article-title":"Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms","volume":"22","author":"Ruggieri","year":"2015","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1074\/jbc.RA120.014960_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1227\/01.NEU.0000188281.91351.B9","article-title":"Epidemiology of intracranial meningioma","volume":"57","author":"Claus","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1074\/jbc.RA120.014960_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","article-title":"The WHO classification of tumors of the nervous system","volume":"61","author":"Kleihues","year":"2002","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1074\/jbc.RA120.014960_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14737175.2018.1429920","article-title":"Current treatment options for meningioma","volume":"18","author":"Apra","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1074\/jbc.RA120.014960_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","article-title":"Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex","volume":"19","author":"McClatchey","year":"2009","journal-title":"Trends Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1534-5807(01)00009-0","article-title":"The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling","volume":"1","author":"Shaw","year":"2001","journal-title":"Dev. Cell"},{"key":"10.1074\/jbc.RA120.014960_bib9","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1158\/0008-5472.CAN-08-0866","article-title":"Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2","volume":"68","author":"Yi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1074\/jbc.RA120.014960_bib10","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/Merlin is a novel negative regulator of mTOR complex 1 and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib11","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor NF2\/Merlin constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"Lopez-Lago","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","author":"Hamaratoglu","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib13","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2013.08.025","article-title":"Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin\/NF2","volume":"154","author":"Yin","year":"2013","journal-title":"Cell"},{"key":"10.1074\/jbc.RA120.014960_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"10.1074\/jbc.RA120.014960_bib15","doi-asserted-by":"crossref","first-page":"16981","DOI":"10.18632\/oncotarget.4858","article-title":"A\u00a0high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas","volume":"6","author":"Beauchamp","year":"2015","journal-title":"Oncotarget."},{"key":"10.1074\/jbc.RA120.014960_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.nbd.2007.09.002","article-title":"Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth","volume":"29","author":"James","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1074\/jbc.RA120.014960_bib17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1074\/jbc.RA120.014960_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1074\/jbc.RA120.014960_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A\u00a04-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1074\/jbc.RA120.014960_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1074\/jbc.RA120.014960_bib21","article-title":"Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2","volume":"13","author":"Allaway","year":"2018","journal-title":"PLoS One"},{"key":"10.1074\/jbc.RA120.014960_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","article-title":"EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma","volume":"20","author":"Angus","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1074\/jbc.RA120.014960_bib23","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","article-title":"Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma","volume":"10","author":"Sagers","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1074\/jbc.RA120.014960_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1074\/jbc.RA120.014960_bib25","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/brain\/awx253","article-title":"Pharmacological targeting of apelin impairs glioblastoma growth","volume":"140","author":"Harford-Wright","year":"2017","journal-title":"Brain"},{"key":"10.1074\/jbc.RA120.014960_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cca.2016.04.001","article-title":"Apelin\/APJ system and cancer","volume":"457","author":"Yang","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1074\/jbc.RA120.014960_bib27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1074\/jbc.RA120.014960_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s11060-018-2922-5","article-title":"Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2","volume":"139","author":"Osorio","year":"2018","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1074\/jbc.RA120.014960_bib29","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1158\/0008-5472.CAN-09-3145","article-title":"An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation","volume":"70","author":"Schoeberl","year":"2010","journal-title":"Cancer Res."},{"key":"10.1074\/jbc.RA120.014960_bib30","doi-asserted-by":"crossref","first-page":"ra31","DOI":"10.1126\/scisignal.2000352","article-title":"Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis","volume":"2","author":"Schoeberl","year":"2009","journal-title":"Sci. Signal"},{"key":"10.1074\/jbc.RA120.014960_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1074\/jbc.RA120.014960_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1074\/jbc.RA120.014960_bib33","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1074\/jbc.RA120.014960_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1074\/jbc.RA120.014960_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphar.2015.00283","article-title":"Role of ErbB receptors in cancer cell migration and invasion","volume":"6","author":"Appert-Collin","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1074\/jbc.RA120.014960_bib36","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1158\/0008-5472.CAN-18-1001","article-title":"ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF\/NRAS melanoma","volume":"78","author":"Capparelli","year":"2018","journal-title":"Cancer Res."},{"key":"10.1074\/jbc.RA120.014960_bib37","doi-asserted-by":"crossref","first-page":"24267","DOI":"10.1074\/jbc.M115.657270","article-title":"Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma","volume":"290","author":"Capparelli","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1074\/jbc.RA120.014960_bib38","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1158\/0008-5472.CAN-14-2959","article-title":"ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF\/NRAS cutaneous melanomas","volume":"75","author":"Capparelli","year":"2015","journal-title":"Cancer Res."},{"key":"10.1074\/jbc.RA120.014960_bib39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ccr.2011.07.011","article-title":"Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers","volume":"20","author":"Wilson","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1074\/jbc.RA120.014960_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/mao.0b013e31815d4429","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy","volume":"29","author":"Doherty","year":"2008","journal-title":"Otol. Neurotol."},{"key":"10.1074\/jbc.RA120.014960_bib41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/onc.2008.427","article-title":"Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas","volume":"28","author":"Lallemand","year":"2009","journal-title":"Oncogene"},{"key":"10.1074\/jbc.RA120.014960_bib42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/01.jnen.0000199575.93794.2f","article-title":"Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis","volume":"65","author":"Stonecypher","year":"2006","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1074\/jbc.RA120.014960_bib43","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1074\/jbc.RA120.014960_bib44","doi-asserted-by":"crossref","first-page":"16034","DOI":"10.1038\/npjsba.2016.34","article-title":"Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)","volume":"3","author":"Schoeberl","year":"2017","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1074\/jbc.RA120.014960_bib45","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009191","article-title":"Insulin receptor signaling in normal and insulin-resistant states","volume":"6","author":"Boucher","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1074\/jbc.RA120.014960_bib46","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.molcel.2017.06.033","article-title":"Focal adhesion- and IGF1R-dependent survival and migratory pathways mediate tumor resistance to mTORC1\/2 inhibition","volume":"67","author":"Yoon","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1074\/jbc.RA120.014960_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib48","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","article-title":"Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies","volume":"14","author":"Shah","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1074\/jbc.RA120.014960_bib49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"10.1074\/jbc.RA120.014960_bib50","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"key":"10.1074\/jbc.RA120.014960_bib51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/ncb2860","article-title":"Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis","volume":"15","author":"Liu","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1074\/jbc.RA120.014960_bib52","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.18632\/oncotarget.3006","article-title":"Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2","volume":"6","author":"Luo","year":"2015","journal-title":"Oncotarget."},{"key":"10.1074\/jbc.RA120.014960_bib53","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1074\/jbc.RA120.014960_bib54","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/labinvest.3700307","article-title":"Establishment of a benign meningioma cell line by hTERT-mediated immortalization","volume":"85","author":"Puttmann","year":"2005","journal-title":"Lab. Invest."},{"key":"10.1074\/jbc.RA120.014960_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1074\/jbc.RA120.014960_bib56","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","article-title":"RNA-SeQC: RNA-seq metrics for quality control and process optimization","volume":"28","author":"DeLuca","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1074\/jbc.RA120.014960_bib57","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1074\/jbc.RA120.014960_bib58","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1074\/jbc.RA120.014960_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1074\/jbc.RA120.014960_bib60","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1074\/jbc.M710257200","article-title":"Epidermal growth factor receptor signaling to Erk1\/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection","volume":"283","author":"Liu","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1074\/jbc.RA120.014960_bib61","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1038\/sj.onc.1208110","article-title":"Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2","volume":"23","author":"Wiederhold","year":"2004","journal-title":"Oncogene"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.RA120.014960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T02:16:05Z","timestamp":1634436965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":61,"alternative-id":["S0021925820001507"],"URL":"https:\/\/doi.org\/10.1074\/jbc.ra120.014960","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.RA120.014960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100157"}}